Preventing kidney injury from strong medications with cilastatin
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether a medicine called cilastatin can prevent kidney damage caused by certain strong medications. If you are receiving one of these medications and are at risk for kidney injury, this trial may offer protection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You are currently receiving a medication that can harm the kidneys, such as certain intravenous antibiotics, anti-rejection drugs, or chemotherapy, or you are getting contrast dye through an artery with at least two other high-risk drugs
- You do not have severe kidney injury or advanced chronic kidney disease (stage 5)
- You are not pregnant or breastfeeding
- You are not allergic to imipenem-cilastatin
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests ways to protect the kidneys in intensive-care patients who have moderate or severe acute kidney injury. If you are on a ventilator or medications to support blood pressure, this study may offer extra kidney care to help prevent further damage.
This study tests whether a supplement called N-acetylcysteine (a type of antioxidant) can help protect the kidneys during cisplatin chemotherapy. Cisplatin is a common cancer drug but can sometimes harm the kidneys, so this trial aims to see if adding this supplement reduces that risk.
This study looks at how cisplatin chemotherapy affects the kidneys. It may help doctors better predict and protect against kidney damage when patients start cisplatin.
This study tests whether giving a medicine called aminophylline can help protect your kidneys from damage caused by cisplatin, a common chemotherapy drug. If it works, it could reduce kidney side effects for people getting cisplatin.
This study tests whether infliximab can treat kidney damage caused by immune checkpoint inhibitor cancer therapy. It aims to see if this medication helps patients recover kidney function after injury from their cancer treatment.
This trial compares two common antibiotic combinations to see which one is less likely to cause kidney injury in hospitalized patients. You may be eligible if you need treatment with vancomycin plus either piperacillin-tazobactam or cefepime.
Hear when a new Acute Kidney Injury trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.